Aquestive Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with unmet medical needs. Founded in 2006, the company has made significant strides in the pharmaceutical industry, particularly in the areas of drug delivery and formulation technologies. Specialising in the development of oral films and other unique delivery systems, Aquestive's core products, such as the Suboxone Film, stand out for their ability to enhance patient compliance and improve therapeutic outcomes. With a commitment to addressing complex medical challenges, the company has established a strong market position, recognised for its advancements in the treatment of opioid dependence and other conditions. Through its dedication to innovation, Aquestive Therapeutics continues to shape the future of patient care.
How does Aquestive Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aquestive Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aquestive Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there is no available emissions data or climate commitments, it is unclear how Aquestive Therapeutics is addressing its carbon footprint or contributing to broader climate goals. The lack of information suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aquestive Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.